Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors

by Vandana Singh, Benzinga Editor

July 22, 2021 9:28 AM | 1 min read |

Adagene Inc ADAG has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc MRK.
The agreement includes two clinical studies to evaluate Adagene's anti-CTLA-4 monoclonal antibody (mAb) candidates, ADG116 and ADG126, in combination with Merck's Keytruda (pembrolizumab), for patients with advanced/metastatic solid tumors.
"ADG116 program is at the 3 mg/kg dose level now, which is where the commercial CTLA-4 therapy had been approved previously in mono and combination for specific indications," said Steven Fischkoff, interim Chief Medical Officer of Adagene.
Price Action: ADAG shares are up 3.97% at $20.67 during the premarket session on the last check Thursday.

Posted In: Biotech News Health Care Contracts Small Cap General Briefs Solid Tumor

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.